UK markets close in 6 hours 23 minutes

Fate Therapeutics, Inc. (FATE)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
7.04-0.45 (-6.01%)
At close: 04:00PM EDT
7.00 -0.04 (-0.57%)
Pre-market: 05:35AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close7.49
Open7.49
Bid7.96 x 1300
Ask8.50 x 1100
Day's range6.95 - 7.50
52-week range1.63 - 8.83
Volume2,264,860
Avg. volume2,876,265
Market cap698.632M
Beta (5Y monthly)1.67
PE ratio (TTM)N/A
EPS (TTM)-1.64
Earnings date01 May 2024 - 06 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est7.53
  • GlobeNewswire

    Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO, March 05, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company granted a non-qualified stock option to one newly-hired employee to purchase a total of 40,000 shares of the Company’s common stock at an exercise price per share of $

  • Insider Monkey

    Fate Therapeutics, Inc. (NASDAQ:FATE) Q4 2023 Earnings Call Transcript

    Fate Therapeutics, Inc. (NASDAQ:FATE) Q4 2023 Earnings Call Transcript February 26, 2024 Fate Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.45, expectations were $-0.57. Fate Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the Fate […]

  • GlobeNewswire

    Fate Therapeutics to Present at Upcoming March Investor Conferences

    SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will participate in the following upcoming investor conferences: TD Cowen’s 44th Annual Health Care Conference on Wednesday, Mar